Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OPK vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: OPK 2 – 4 VCYT Matrix Metrics: OPK 3 – 7 VCYT

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Opko Health Inc. (OPK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). OPK carries a Unified Composite Score of 38.6/100 (SELL) at $1.62 (53.8x Forward P/E, -27.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Technical & Structure Timing Caution: OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OPK vs VCYT
OPK NASDAQ
Opko Health Inc.
Pharmaceutical Preparations
$1.62
-3.57% 1D
Market Cap $1.2B
TTM Revenue $654M
Forward P/E 53.8x
Beta / 30D Vol 0.77β · 31% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 30.0 Fund 43.0 Flow 65.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $1.67 · SMA50: $1.60
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (OPK 2 – 4 VCYT)

Columns: Metric · OPK · VCYT
1. Valuation Multiples VCYT
Forward P/E 53.8x 15.3x
Trailing P/E 53.8x 15.8x
PEG Ratio N/M N/M
EV / Revenue 2.1x 3.1x
2. Growth & Scale OPK
Revenue Growth (YoY) +15.9% +15.1%
Earnings Growth (YoY) -12.6% +58.3%
TTM Revenue (USD) $654M $582M
Market Cap $1.2B $2.0B
3. Profitability & Quality VCYT
Gross Margin 19.6% 74.2%
Operating Margin -27.8% 15.0%
Net Profit Margin -22.6% 21.8%
Return on Equity (ROE) -8.9% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) -$136M $162M
Cash Flow Margin -20.8% 27.8%
Net Cash / Leverage $125M Net Debt (0.46x D/E) $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OPK
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 58.9% (3rd %ile) 197.3% (47th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 47.4% of Rev ($310M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OPK (3) vs VCYT (7)
Institutional Metric OPK VCYT Criterion Row Edge
Market Capitalization
Scale
$1.2B $2.0B Larger Scale VCYT
Trailing P/E Ratio
Valuation
53.8x 15.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
53.8x 15.3x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.9% +15.1% Higher Growth OPK
Operating Margin (TTM)
Profitability
-27.8% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
-22.6% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
-8.9% 9.4% Higher ROE VCYT
52-Week Range Position
Momentum
73% ($1–$2) 5% ($22–$61) Stronger Trend OPK
Beta / 30D Volatility
Risk Regime
0.77β · 31% Vol 3.01β · 199% Vol Lower Realized Risk OPK
Unified Institutional Score
Composite Signal
38.6 / 100 (SELL) 49.1 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$654M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
19.6% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.1x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$136M ($125M Net Debt (0.46x D/E)) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OPK +50.2 pp
OPK: +5.88% · VCYT: -44.32%
3M Horizon OPK +60.1 pp
OPK: +19.12% · VCYT: -40.98%
6M Horizon OPK +85.5 pp
OPK: +43.36% · VCYT: -42.14%
1Y Horizon OPK +66.34 pp
OPK: +26.56% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OPK Revenue VCYT Revenue OPK Op. Margin VCYT Op. Margin Margin Leader
FY2018 $990M $90M -17.3% -24.2% OPK
FY2019 $900M $120M -30.4% -12.6% VCYT
FY2020 $1.44B $120M 4.0% -30.1% OPK
FY2021 $1.77B $220M 1.1% -37.3% OPK
FY2022 $1.00B $300M -22.5% -13.9% VCYT
FY2023 $860M $360M -18.2% -23.8% OPK
FY2024 $710M $450M -21.3% 3.6% VCYT
FY2025 $610M $520M -19.3% 11.2% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OPK CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 58.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OPK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OPK Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.2B market capitalization and -27.8% operating margin.
OpEx & R&D Reinvestment 47.4% of Rev ($310M)
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ OPK vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Opko Health Inc. (OPK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). OPK carries a Unified Composite Score of 38.6/100 (SELL) at $1.62 (53.8x Forward P/E, -27.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: OPK trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OPK leads the Growth & Scale pillar: OPK posts +15.9% YoY revenue growth and -12.6% YoY earnings growth on $654M TTM revenue (19.6% gross margin, -27.8% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OPK cumulative revenue shifted -38.4% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, OPK deploys 47.4% of Rev ($310M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

VCYT screens cheaper on headline valuation multiples. OPK trades at 53.8x Forward P/E, 53.8x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-20.8% FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OPK (-8.9% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, OPK carries 58.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 31% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.